Cancer cell membrane-derived nanoparticles improve the activity of gemcitabine and paclitaxel on pancreatic cancer cells and coordinate immunoregulatory properties on professional antigen-presenting cells

Abstract

Human pancreatic carcinoma is amid the neoplasias with the highest number of deaths and the frequency of relapses has demanded novel therapeutic intervention. Currently, the simultaneous application of different chemotherapeutics...

Nanoengineered cell membrane-based nanoparticles for tumor and immunocompetent cells modulation

“…Based on the improvement provided in terms of therapeutic efficacy and its immunological aspects, paclitaxel-loaded nanoparticles (Abraxane ® ) exhibit not only a slight cytotoxicity in peripheral monocytes in the bloodstream, but also does not induce phenotypic changes. [74][75] Exposure of peripheral blood monocytes with NPs-PTX during their in vitro differentiation to DCs did not decrease the expression of CD11c, CD209, and MHC-II. 75 Additionally, NPs-PTX do not interfere with the stimulatory ability of DCs or suppress the capacity to stimulate naive T cells, with no phenotypic and functional changes observed in mature DCs.…”

“…112 In another study, we reported the use of MNPs for conducting encapsulation of two first-line drugs used in pancreatic cancer treatment. 74 The MNPs were isolated from the pancreatic membrane and incorporated with gemcitabine and paclitaxel to induce apoptosis in PANC-1 cell lines in vitro. Furthermore, the antigenic material carried in the nanovesicles activated human monocytes and DCs in the presence of chemotherapeutic molecules.…”

“…[129][130] Recently, nanostructures loaded with gemcitabine showed a higher cytotoxic effect in pancreatic cancer cells than pure chemotherapeutic in vitro. 180 In the same study, it was demonstrated that nanovesicles fabricated with membrane lipids (phospholipids, glycolipids, and cholesterol) are very stable in the culture medium. 180 We synthesized lipid nanoparticles with the main components from the prostate cancer cell membrane to deliver CTX (MNPs-CTX) in malignant cells aiming at reducing drug cytotoxic activity in healthy cells.…”

“…180 In the same study, it was demonstrated that nanovesicles fabricated with membrane lipids (phospholipids, glycolipids, and cholesterol) are very stable in the culture medium. 180 We synthesized lipid nanoparticles with the main components from the prostate cancer cell membrane to deliver CTX (MNPs-CTX) in malignant cells aiming at reducing drug cytotoxic activity in healthy cells. Nanoparticle specificity was checked after exposing them to PC-3 cell line, demonstrating that MNPs can be used to targeted drug molecules in diseased cells in the future.…”

“…For example, nanoengineering procedures isolate lipids and proteins from cellular surfaces to synthesize nanovesicles with the major components of the plasmatic membrane (MNPs). 74,[112][113][114][115][116] The presence of cellular adhesion proteins improves nanostructure specificity, with excellent internalization by the cells where membrane residues came from. [129][130] Recently, nanostructures loaded with gemcitabine showed a higher cytotoxic effect in pancreatic cancer cells than pure chemotherapeutic in vitro.…”